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Abstract 
Background: Progressive multifocal leukoencephalopathy (PML) is a demyelinating 
central nervous system disease caused by JC virus (JCV) reactivation in 
immunocompromised patients. The disease course of PML is often progressive, fatal and 
at present, there are few reports on successful treatment outcomes.  
Case Report: A 45-year-old man with systemic sarcoidosis presented with rapidly 
progressive dementia and right hemiparesis. The patient was diagnosed with PML as 
confirmed via brain biopsy and JCV PCR. With a combination treatment of cidofovir and 
mirtazapine, there was significant improvement of neurological symptoms without 
measurable functional deficit.  
Conclusion: This case suggests that dual therapy with cidofovir and mirtazapine might 
be an effective treatment option in PML patients with sarcoidosis. 
 
Introduction 
Progressive multifocal leukoencephalopathy (PML) is a deadly demyelinating central 
nervous system disease caused by reactivation of the JC virus (JCV). It can occur in 
immunocompromised patients including those with acquired immune deficiency 
syndrome, hematological malignancies, post-transplantation on immunosuppressive Case Rep Neurol 2011;3:258–262 
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therapy and sarcoidosis [1]. The disease course of PML is usually progressive and fatal. 
Recent studies have revealed potential therapeutic agents for PML but their efficacy has 
remained inconsistent. Here, we report a case of PML in a sarcoidosis patient who 
showed nearly complete recovery after a dual therapy regimen with cidofovir and 
mirtazapine. 
Case Report 
A 45-year-old man was admitted with progressive cognitive impairment and right hemiparesis that 
began 1 month prior. Four months prior to admission, he had been diagnosed with systemic sarcoidosis 
involving his lungs, liver, spleen, abdominal and mediastinal lymph nodes, as revealed through 
bronchoscopic lung biopsy. Treatment for sarcoidosis began with 15 mg of prednisone, once daily for 5 
weeks, proceeded by 10 mg for the following 4 weeks, and then 5 mg of prednisone as a maintenance dose. 
Upon admission, neurological examination revealed right facial palsy (central type) and right 
hemiparesis (MRC grade III in his right arm and grade IV in his right leg). He also displayed decreased 
cortical sensation on his right side, Gerstmann syndrome, ideomotor apraxia, optic ataxia and optic 
apraxia. His Mini-Mental State Examination (MMSE) score (Korean version) was 19/30 with errors in 
orientation for time, orientation for place, delayed recall, serial sevens, writing and interlocking 
pentagon drawing. Results of the Seoul Neuropsychological Screening Battery showed cognitive 
impairment in multiple domains including language, visuospatial, memory and frontal executive 
function. Serum anti-HIV antibody and HIV antigen tests were negative. Cerebrospinal fluid (CSF) 
findings were within the normal range. Brain MRI demonstrated bilateral multifocal white matter 
lesions which were hypointense on T1-weighted imaging and hyperintense on T2-weighted imaging 
with surrounding edema. No such enhancement occurred on gadolinium-enhanced T1-weighted 
imaging. Diffusion-weighted imaging revealed a diffusion-restricted peripheral rim with central 
vasogenic edema, consistent with demyelinating plaques (fig. 1). A brain biopsy was performed, 
revealing virus-infected oligodendrocytes, active demyelination and reactive astrocytes within the lesion 
(fig. 2). The JCV PCR test performed on brain tissue was positive, establishing the diagnosis of PML. 
During the 10 days of hospitalization before treatment, the patient’s neurological status displayed 
continuing deterioration, despite discontinuance of prednisone. Dual therapy with cidofovir and 
mirtazapine (5 mg/kg intravenous cidofovir weekly for the first 2 weeks followed by biweekly 
administration of the same dose, and 15 mg of oral mirtazapine daily) was started. The patient’s 
symptoms began to improve gradually from 4 days after treatment. At discharge, 3 weeks after initiation 
of treatment, motor power had recovered to MRC grade IV on the upper extremity and MRC grade V 
on the lower extremity, while the MMSE score had improved to 22/30. Four months after being 
discharged, treatment was discontinued due to increased levels of urine protein (105 mg/dl). At that 
point, a marked clinical improvement was observed. Motor power in the right arm and leg was nearly 
completely restored and the MMSE score was 30. There has been no reported relapse of neurological 
symptoms during the 16 months of follow-up after discharge. 
Discussion 
The clinical and pathological findings suggested that the rapidly progressive dementia 
displayed in this patient with sarcoidosis was a direct result of PML. Our case report 
suggests that dual therapy with cidofovir and mirtazapine could be a viable therapeutic 
option for PML patients with sarcoidosis. 
To date, there exist few reports of PML associated with sarcoidosis. In one study 
summarizing 58 non-HIV patients with PML, 9% of the patients had sarcoidosis as an 
underlying disease [2]. Whether the cause of coincidental sarcoidosis and PML is 
secondary to immunosuppressive treatment or a reflection of underlying immunological 
defect remains unclear. Although most of the reported patients with sarcoidosis were on Case Rep Neurol 2011;3:258–262 
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immunosuppressive treatment such as oral corticosteroids or azathioprine [3–5], it could 
have been the first manifestation of sarcoidosis [6] or possibly have developed in patients 
with untreated sarcoidosis [7]. There are several explanations of pathogenesis for the 
development of PML in sarcoidosis. A state of anergy (poor response to antigens) and/or 
increased activity of regulatory T lymphocytes, commonly observed in patients with 
sarcoidosis may be the cause of PML [8]. Additionally, the shift in CD4/CD8-ratio due to 
a lack of JC virus-specific cytotoxic T cells may also induce the development of PML [4]. 
The diagnosis of PML in patients with sarcoidosis remains challenging. Initially, our case 
could also have been considered to be neurosarcoidosis due to the symptoms occurring 
during steroid dose tapering. Although the most common abnormality of neurosarcoidosis 
is involvement of the basal meninges that subsequently affect the cranial nerves, 
accumulation of granulomas in the brain can lead to progressive dementia [9]. Additionally, 
current imaging techniques often cannot distinguish PML from neurosarcoidosis. 
Neurosarcoidosis often presents with multiple supratentorial or infratentorial white matter 
lesions without meningeal involvement, which is similar to the lesions occurring in PML 
[9]. However, it is highly important to differentiate PML from neurosarcoidosis due to their 
different treatment requirements. Neurosarcoidosis is usually treated with steroid therapy, 
whereas steroid therapy would enhance JCV activity in PML. Therefore, we recommend 
that a brain biopsy or CSF JCV PCR be promptly performed in cases where rapidly 
progressive dementia is thought to be the result of neurosarcoidosis or PML. 
The disease course of PML is generally known to be progressive and fatal. The median 
survival of patients without HIV infection is only a few months. Previous animal studies 
have shown that several therapeutic agents may be effective in the treatment of PML [10]. 
More recent case reports suggest that cidofovir and a 5-HT2A blocker could be effective 
against PML [3, 7]. Cidofovir is a nucleotide analogue, displaying effective anti-JCV 
activity in a mouse polyomavirus model [11]. The anti-depressant mirtazapine blocks a 
substantial number of 5-HT2A receptors that JCV employs to infect human glial cells [12]. 
In this case study, the ongoing neurological deterioration until the introduction of 
cidofovir and mirtazapine suggests that this therapeutic agent played a role in the 
patient’s recovery. However, there exist case reports that did not show cidofovir to be 
effective in PML patients with sarcoidosis [4, 5, 13]. All of these previous cases were 
initially treated with a high dose of intravenous methylprednisolone, due to a 
misdiagnosis of neurosarcoidosis or acute disseminated encephalomyelitis followed by 
further deterioration. They were later correctly diagnosed as having PML by brain biopsy. 
Although cidofovir was administered, all the patients died. Thus, we believe that PML 
should be considered in patients with sarcoidosis presenting with rapidly progressive 
dementia, and in such cases, the diagnosis must be confirmed before steroid therapy is 
initiated. Further studies are needed to determine the causal relationship, optimal dose 
and duration for treatment. 
Acknowledgement 
The authors thank Lee Farrand at Seoul National University for English editing. 
Disclosure Statement 
The authors declare no financial conflicts of interest. Case Rep Neurol 2011;3:258–262 
DOI: 10.1159/000333780 
Published online: 
October 14, 2011 
© 2011 S. Karger AG, Basel
ISSN 1662–680X 






Fig. 1. Brain MRI showing bilateral multifocal white matter lesions. The lesions contain high signal-
intense rims on diffusion-weighted images (a). With low signal intensity on an afferent diffusion 
coefficient map (b). The findings are consistent with demyelinating plaque. c T2-weighted images 
display hyperintense lesions with surrounding edema. d Gadolinium-enhanced T1-weighted image 
does not reveal an enhanced lesion area. 
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Fig. 2. Neuropathological findings. a The enlarged oligodendrocyte (arrow) contains a glassy nucleus, 
characteristic of viral inclusion bodies combined with reactive astrocytes (asterisks) (hematoxylin-eosin, 
×400). The macrophages (arrowheads) contain cytoplasmic myelin particles, indicating active 
demyelination. b Myelin particles (arrowheads), stained in blue (Luxol fast blue, ×400). 
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